Pharmascience Launches ᴾʳpms-Nilotinib Capsules

The oral capsules, available in 150 mg and 200 mg strengths, are now on the Canadian market from the Montreal-based company.

Updated on Nov. 17, 2026 in Cancer

Smooth unlabeled capsules rest on a pale countertop beside a glass of water in a bright, uncluttered clinical room.
Pharmascience Canada launched ᴾʳpms-NILOTINIB oral capsules in 150 mg and 200 mg strengths, adding a new oral option to the Canadian market. AI Illustration. Upload story photo >

Pharmascience Canada has launched ᴾʳpms-NILOTINIB oral capsules in the Canadian market, available in strengths of 150 mg and 200 mg. Patients are directed to consult their healthcare professional to determine whether the treatment is appropriate for them.

Why it matters

The launch adds a new oral option to the Canadian market, and the product monograph provides prescribing details for clinicians and patients. The announcement also highlights Pharmascience's growing domestic footprint as a privately held, fully integrated pharmaceutical company.

The product comes in 150 mg and 200 mg oral capsule strengths, and Pharmascience employs nearly 1,700 people and distributes products in over 50 countries. The announcement does not specify pricing, reimbursement status or provincial listing timelines.

The players

Pharmascience inc.

A privately held, fully integrated Montreal-based pharmaceutical company founded in 1983 that distributes its products in more than 50 countries.

The details

ᴾʳpms-NILOTINIB is available as oral capsules, and the full product monograph is available through a provided link and from the company's Medical Information Department by email or telephone. Pharmascience inc., founded in 1983 and headquartered in Montreal, is the largest pharmaceutical employer in Quebec.

Timeline

  1. In 1983, Pharmascience inc. was founded.

  2. In 2025, the company ranked 41st among Canada's top 100 investors in research and development.

  3. In 2026, Pharmascience was certified as a Great Place to Work for the fifth consecutive year.

  4. On November 17, 2026, the ᴾʳpms-NILOTINIB launch was announced in Canada.

Industry Context

Pharmascience's 2025 ranking as the 41st largest R&D investor among Canada's top 100 reflects its $55 million annual investment, which underpins new product launches such as ᴾʳpms-NILOTINIB. The launch continues that pattern of domestic pharmaceutical development and commercialization.

Patients considering this treatment should consult their healthcare professional to determine whether it is appropriate for them. The product monograph provides full prescribing information, and the Medical Information Department can answer questions by email or telephone.

The takeaway

Anyone considering a new oral cancer therapy should review the full product monograph and discuss eligibility with a healthcare professional before making decisions. Official prescribing information remains the most reliable source for dosing and safety details.

Further reading

Explore more cancer treatment news covering new therapies available in Canada.

More information

Read the ᴾʳpms-NILOTINIB product monograph for full prescribing details.

Source note: This article includes information reported by The Manila times.